What is the role of pharmacologic therapy for multiple system atrophy (MSA)?

Updated: Oct 17, 2018
  • Author: André Diedrich, MD, PhD; Chief Editor: Selim R Benbadis, MD  more...
  • Print

As previously mentioned, pharmacologic therapy for multiple system atrophy (MSA) is directed mainly toward alleviation of symptoms of the movement disorder and orthostatic hypotension (see Table 9, below). Medications can also be used to treat urinary incontinence, constipation, erectile dysfunction, and supine hypertension. In recent years, neuroprotective therapy has been successfully applied in the mouse model. [37] But studies in humans (e.g., rifampicin rasagiline) did not show beneficial effects on slowing down the disease. [38, 39] Transgenic MSA mouse models do not have the same human phenotype but may be the best choice to explore new therapies. [40]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!